Expression of ERCC1, MSH2 and PARP1 in Non-small Cell Lung Cancer and Prognostic Value in Patients Treated with Platinum-based Chemotherapy

Xie, Ke-Jie; He, Hong-Er; Sun, Ai-Jing; Liu, Xi-Bo; Sun, Li-Ping; Dong, Xue-Jun

추천

검색

자료유형: 학술저널

저자정보: Xie, Ke-Jie (Clinical Examination Center, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) He, Hong-Er (Department of Radiotherapy, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) Sun, Ai-Jing (Department of Pathology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) Liu, Xi-Bo (Department of Pathology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) Sun, Li-Ping (Department of Pathology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) Dong, Xue-Jun (Clinical Examination Center, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제6호

발행연도: 2014.1

수록면: 2,591 - 2,596 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: To evaluate the prognostic value of the expression of excision repair cross-complementation group l (ERCC1), MutS protein homolog 2 (MSH2) and poly ADP-ribose polymerase 1 (PARP1) in non-small-cell lung cancer patients receiving platinum-based postoperative adjuvant chemotherapy. Methods: Immunohistochemistry was applied to detect the expression of ERCC1, MSH2 and PARP1 in 111 cases of non-small cell lung cancer paraffin embedded surgical specimens. Through og-rank survival analysis, we evaluated the prognostic value of the ERCC1, MSH2, PARP1 and the related clinicopathological factors. COX regression analysis was used to determine whether ERCC1, MSH2 and PARP1 were independent prognostic factors. Results: In the enrolled 111 non-small cell lung cancer patients, the positive expression rate of ERCC1, MSH2 and RARP1 was 33.3%, 36.9% and 55.9%, respectively. ERCC1 (P<0.001) and PARP1 (P=0.033) were found to be correlated with the survival time while there was no correlation for MSH2 (P=0.298). Patients with both ERCC1 and PARP1 negative cancer had significantly longer survival time than those with ERCC1 (P=0.042) or PARP1 (P=0.027) positive alone. Similalry, the survival time of patients with both ERCC1 and PARP1 positive cancer was shorter than those with ERCC1 (P=0.048) or PARP1 (P=0.01) positive alone. Conclusion: Patients with ERCC1 or PARP1 negative non-small cell lung cancer appear to benefit from platinum-based postoperative adjuvant chemotherapy.

#DNA repair gene #ERCC1 #MSH2 #RARP1 #non-small cell lung cancer #prognosis #chemotherapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Xie, Ke-Jie

소속기관 Clinical Examination Center, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University